WallStreetZenWallStreetZen

NASDAQ: AKBA
Akebia Therapeutics Inc Stock

$1.10+0.01 (+0.92%)
Updated May 24, 2024
AKBA Price
$1.10
Fair Value Price
N/A
Market Cap
$230.56M
52 Week Low
$0.78
52 Week High
$2.48
P/E
-4.78x
P/B
-8.46x
P/S
2x
PEG
N/A
Dividend Yield
N/A
Revenue
$187.23M
Earnings
-$43.03M
Gross Margin
65%
Operating Margin
-19.26%
Profit Margin
-23%
Debt to Equity
-9.27
Operating Cash Flow
-$25M
Beta
1.49
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AKBA Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKBA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKBA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKBA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AKBA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AKBA due diligence checks available for Premium users.

Be the first to know about important AKBA news, forecast changes, insider trades & much more!

AKBA News

Valuation

AKBA fair value

Fair Value of AKBA stock based on Discounted Cash Flow (DCF)
Price
$1.10
Fair Value
-$0.01
Undervalued by
20,249.70%
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AKBA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.78x
Industry
15.58x
Market
32.03x

AKBA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-8.46x
Industry
6.08x

AKBA's financial health

Profit margin

Revenue
$32.6M
Net Income
-$18.0M
Profit Margin
-55.2%
AKBA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AKBA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$225.5M
Liabilities
$252.7M
Debt to equity
-9.27
AKBA's short-term assets ($112.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKBA's long-term liabilities ($186.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKBA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.4M
Investing
$0.0
Financing
$18.5M
AKBA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AKBA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AKBA$230.56M+0.92%-4.78x-8.46x
IVVD$230.28M-3.98%-1.03x1.29x
QURE$231.10M0.00%-0.77x1.57x
QSI$229.74M-2.41%-2.49x0.91x
TSVT$231.84M+2.50%-1.04x1.12x

Akebia Therapeutics Stock FAQ

What is Akebia Therapeutics's quote symbol?

(NASDAQ: AKBA) Akebia Therapeutics trades on the NASDAQ under the ticker symbol AKBA. Akebia Therapeutics stock quotes can also be displayed as NASDAQ: AKBA.

If you're new to stock investing, here's how to buy Akebia Therapeutics stock.

What is the 52 week high and low for Akebia Therapeutics (NASDAQ: AKBA)?

(NASDAQ: AKBA) Akebia Therapeutics's 52-week high was $2.48, and its 52-week low was $0.78. It is currently -55.65% from its 52-week high and 41.03% from its 52-week low.

How much is Akebia Therapeutics stock worth today?

(NASDAQ: AKBA) Akebia Therapeutics currently has 209,596,378 outstanding shares. With Akebia Therapeutics stock trading at $1.10 per share, the total value of Akebia Therapeutics stock (market capitalization) is $230.56M.

Akebia Therapeutics stock was originally listed at a price of $26.70 in Mar 20, 2014. If you had invested in Akebia Therapeutics stock at $26.70, your return over the last 10 years would have been -95.88%, for an annualized return of -27.31% (not including any dividends or dividend reinvestments).

How much is Akebia Therapeutics's stock price per share?

(NASDAQ: AKBA) Akebia Therapeutics stock price per share is $1.10 today (as of May 24, 2024).

What is Akebia Therapeutics's Market Cap?

(NASDAQ: AKBA) Akebia Therapeutics's market cap is $230.56M, as of May 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akebia Therapeutics's market cap is calculated by multiplying AKBA's current stock price of $1.10 by AKBA's total outstanding shares of 209,596,378.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.